Hepatocellular carcinoma is the most common primary liver malignancy, accounting for 85 to 90 percent of cancers that originate in liver cells, and it ranks as the third leading cause of cancer-related death worldwide. For patients with intermediate-stage disease and preserved liver function, transarterial chemoembolization, or TACE, is a cornerstone of care under the Barcelona Clinic Liver Cancer staging system. The procedure exploits a biological quirk: liver tumors draw their blood supply almost exclusively from the hepatic arteries, while healthy liver tissue depends on the portal vein. By threading a catheter into the arteries feeding the tumor and delivering a mixture of chemotherapy and an oily contrast agent called lipiodol, followed by embolization with gel foam slurry, interventional radiologists can concentrate a cytotoxic assault on the tumor while starving it of blood.

Yet the very act of delivering that assault exposes the hepatic vasculature to a barrage of insults. Catheters and guidewires scrape the vessel walls. Lipiodol and antimitotic drugs such as epirubicin exert corrosive and chemical effects on the delicate endothelial lining. Temporary embolization produces ischemic stress, and patients with chronic liver disease already harbor dysfunctional endothelium that may be poorly equipped to recover. Despite decades of TACE practice, the literature on what actually happens to the native hepatic arteries after treatment has remained surprisingly thin, prompting the research team to investigate systematically.

The researchers, led by interventional radiologists at the Sree Chitra Tirunal Institute for Medical Sciences and Technology in Thiruvananthapuram, Kerala, combed hospital records for all adult patients with chronic liver disease who underwent more than one session of TACE between January 2018 and June 2023. Of 394 patients treated during that window, 69 had undergone repeat sessions, and 58 had angiographic images of sufficient quality for analysis. The team deliberately excluded patients who had received other locoregional therapies, such as radiofrequency ablation, between TACE sessions, to keep the vascular picture as clean as possible.

The analytical framework was elegantly simple. The hepatic vasculature was divided into three anatomical zones: the proximal zone comprising the common hepatic artery and hepatic artery proper, the intermediate zone covering lobar and segmental branches, and the distal zone encompassing the subsegmental branches that represent the liver’s microvascular frontier. Injury was graded on a four-point ordinal scale, ranging from Grade 0 for a normal appearance or mild irregularity, through Grade 1 for mild stenosis of about 50 percent, to Grade 2 for severe stenosis or complete occlusion, and Grade 3 for the presence of pseudoaneurysms or dysplastic arterial changes. Grades 0 and 1 were classified as low-grade injury, while Grades 2 and 3 counted as high-grade. Two radiologists with ten and five years of gastrointestinal imaging experience independently reviewed paired angiograms obtained at least six weeks apart, blinded to clinical details.

The results painted a strikingly zonal picture. In the proximal vessels, 98.3 percent of patients showed Grade 0 injury and the remainder Grade 1, with no high-grade damage at all, and statistical testing confirmed no significant change before and after the first TACE session. The intermediate zone told a different story: 84.5 percent of patients had Grade 0 injury, but 13.8 percent showed Grade 1 and 1.7 percent showed Grade 2, a distribution that shifted significantly after treatment. The distal subsegmental vasculature fared worst of all, with 53.4 percent of patients at Grade 0, 31 percent at Grade 1, 13.8 percent at Grade 2, and 1.7 percent at Grade 3, meaning roughly 12 to 15.5 percent of patients developed high-grade injury to the liver’s smallest arteries. The Mann-Whitney U-test yielded p-values of 0.002 for the intermediate zone and 0.001 for the distal zone, while the proximal zone showed no significant difference. Interobserver agreement was strong, with a correlation coefficient of 0.913.

To understand why some patients’ microvasculature fared worse than others, the team turned to multinomial logistic regression, feeding in demographic, biochemical, clinical and procedural variables. Three factors emerged as independent predictors of high-grade distal arterial injury: the Child-Pugh score, a measure of liver functional reserve; the presence of diabetes; and the delta time, the interval in weeks between successive TACE sessions. Each carried a statistically significant association, with p-values of 0.031, 0.045 and 0.004 respectively. Notably, no variable predicted high-grade injury in the lobar and segmental vessels, reinforcing the impression that the microvasculature is uniquely vulnerable.

The biology behind these predictors is plausible. Diabetes is well known to impair endothelial function and blunt vascular healing, and prior work has shown that adequate glycemic control in TACE patients is associated with improved progression-free survival. Deteriorating liver function, captured by the Child-Pugh score, is likewise linked to poor endothelial resilience and impaired microvascular recovery. The delta time finding may be the most immediately actionable: shorter intervals between embolization sessions give the injured native vasculature less time to recover, so repetitive injury at close intervals compounds itself. This inverse relationship between retreatment interval and vascular damage could inform scheduling decisions, suggesting that clinicians may want to prioritize vascular recovery when planning repeat interventions rather than compressing the timeline.

The clinical stakes are considerable. Patency of segmental and subsegmental arteries is paramount for delivering a second round of chemoembolization to residual or recurrent tumor, so distal vascular injury could compromise both the feasibility and efficacy of retreatment, and may even encourage the tumor to recruit alternative extrahepatic blood supplies. Conversely, the apparent invulnerability of the proximal hepatic arteries is reassuring for the substantial subset of patients who undergo TACE as a bridge to liver transplantation, since damage to the main hepatic artery could complicate the transplant operation itself. Prior multicenter analyses of more than 800 patients who received TACE before transplantation found no increased need for intraoperative hepatic artery interventions, a conclusion this study’s proximal findings echo. The authors also raise the possibility that transarterial radioembolization, generally considered gentler on the vasculature, may be preferable for patients anticipated to need multiple locoregional treatments.

The study has limitations that temper but do not erase its message. It assessed only the changes following the first TACE session to maintain homogeneity, so cumulative injury from multiple sessions remains unmeasured. It was a single-center analysis with a modest sample, and all patients received conventional TACE rather than drug-eluting bead or balloon-occlusion variants, so the findings may not generalize to those techniques. Still, the authors report that no previous study has systematically documented the incidence of hepatic arterial injury after chemoembolization, making this a genuine first. Larger, prospective, multicenter trials will be needed to confirm the predictors and to determine whether protecting the liver’s smallest arteries can translate into better outcomes for patients facing repeated rounds of therapy against one of the world’s deadliest cancers.

Subject of Research: Vascular injury to hepatic arteries following transarterial chemoembolization for hepatocellular carcinoma

Article Title: Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study

Article References: Arunachalam, V. S., Sharma, S., Ayyappan, A., Alex, A., & Valakkada, J. (2025). Angio-architectural changes in hepatic arteries following conventional transarterial chemoembolization for hepatocellular carcinoma and the factors influencing them: a retrospective observational study. CVIR Oncology, 1(1), Article 28. https://doi.org/10.1007/s44343-025-00028-w

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00028-w

Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery, vascular injury, interventional radiology, angiography, microvasculature, Child-Pugh score, diabetes, lipiodol, liver cancer, endothelial dysfunction

The clinical rationale for expanding access is grounded in shifting epidemiology. Hepatocellular carcinoma, the most common primary liver cancer, has risen substantially in incidence and mortality in the United States and worldwide, increasingly driven by non-viral causes such as metabolic-dysfunction-associated steatotic liver disease, or MASLD. Current American Association for the Study of Liver Diseases guidelines do not recommend routine surveillance for most MASLD patients unless they develop cirrhosis, which means many tumors are caught at later stages. With roughly two-thirds of patients falling into the intermediate or advanced categories of the Barcelona Clinic Liver Cancer staging system, where liver-directed therapies play a central and evolving role, the authors contend that improved access to these treatments is essential to meet a growing healthcare burden.

Radioembolization works by threading millions of microscopic beads loaded with yttrium-90, a beta-emitting radionuclide, through the hepatic artery directly into the vessels feeding a tumor. The radiation travels an average of only a few millimeters in tissue, delivering tumoricidal doses while sparing much of the surrounding liver. Over the past two decades the technique has moved from lobar, body-surface-area-based dosing toward superselective, segmental delivery guided by personalized dosimetry. That shift has transformed its role. Radiation segmentectomy, in which an ablative dose is concentrated in one or two liver segments, has created a curative-intent option for selected patients with early-stage disease who are not ideal candidates for surgery or thermal ablation.

The evidence supporting this evolution is now substantial. Early randomized trials comparing radioembolization with the drug sorafenib, including SARAH and SIRveNIB, showed no overall survival advantage, but those studies predate modern patient selection and dosimetry. A post hoc analysis of SARAH found that patients receiving adequate tumor absorbed dose derived greater benefit, pointing directly at dosimetry as the missing variable. The randomized DOSISPHERE-01 trial then demonstrated improved objective response rates and overall survival when dosing was personalized to maximize tumor absorbed dose compared with standard approaches. Studies such as LEGACY, RASER, and DOORwaY90 have since shown high response rates with segmental high-dose delivery, and comparative trials including TRACE and PREMIERE suggest potential advantages over chemoembolization in selected patients, including longer time to progression and fewer treatment sessions.

In the transplant arena, radioembolization has become the most commonly used liver-directed therapy in the United States for bridging and downstaging patients awaiting a new liver. A key metric is complete pathologic necrosis, the disappearance of viable tumor on examination of the explanted liver, which radioembolization achieves at consistently high rates compared with other locoregional therapies and which is associated with better post-transplant outcomes. Emerging data suggest, however, that factors beyond mean tumor dose, such as microsphere-specific activity, particle density, and spatial dose heterogeneity, may independently influence the radiobiologic effect. Because glass and resin microspheres differ substantially in these properties, the authors caution that dose targets and delivery strategies may not be interchangeable across platforms, and future guidelines should account for microsphere type, treated vascular territory, and the intended biologic endpoint.

Regulatory milestones have accelerated adoption. The U.S. Food and Drug Administration granted premarket approval for TheraSphere glass microspheres for unresectable hepatocellular carcinoma in March 2021, while SIR-Spheres resin microspheres, approved in 2002 for colorectal liver metastases, received an added unresectable HCC indication in 2025. Unified practice parameters, including the 2023 ACR-ABS-ACNM-ARS-SIR-SNMMI practice parameter, have standardized patient selection, lung shunt assessment, dose planning, and radiation safety, making results more reproducible across centers. But standardization also raises the bar: a credible program now requires reliable nuclear medicine collaboration, dosimetry support, trained interventional radiology staff, consistent imaging protocols, and a system for tracking outcomes.

The operational heart of the review is a detailed team structure. Interventional radiologists lead protocol development, case selection, dosimetry oversight, and informed consent, supported by nurses, technologists, and advanced practice providers. Medical physicists implement and audit dosimetric protocols; nuclear medicine physicians and radiopharmacists manage the radiotracer and interpret lung shunt and post-therapy imaging; and hepatology, oncology, transplant surgery, diagnostic radiology, and palliative care contribute through a multidisciplinary tumor board. A standardized pathway converts this structure into reproducible care, moving patients from referral intake through tumor board presentation, interventional radiology clinic visits, mapping angiography with technetium-99m MAA imaging, dosimetric review, treatment, and structured follow-up. Quality is monitored with pragmatic metrics: process measures such as time from referral to treatment and a work-up completion rate above 90 percent as an aspirational benchmark, clinical measures such as response rates and downstaging success, and safety measures tracking unplanned admissions, gastrointestinal ulceration, radiation pneumonitis, and deterioration in liver function within 90 days.

A recurring theme is the central role of the dedicated nurse coordinator, who serves as the program’s operational and clinical liaison. Within the boundaries of nursing scope of practice, the coordinator navigates patients through the pathway, prepares families for the logistics of separate mapping and treatment visits, coordinates authorizations and appointments across services, and conducts structured post-procedure check-ins to catch symptoms early. The authors emphasize that this role often becomes the most continuous point of contact for patients and families, providing emotional support and a trusted space for questions throughout a protracted treatment journey. Patient decision aids, including bilingual tools developed by the Interventional Initiative, have been shown in clinical trials to improve understanding and satisfaction before informed consent conversations.

The review also confronts the business case frankly. Hospitals that refer radioembolization cases out lose revenue from the entire episode of care, including imaging, clinic visits, mapping procedures, nuclear medicine studies, and follow-up. A make-versus-buy analysis must weigh fixed assets such as angiography suites and dosimetry software against variable costs and projected volume; a program may be profitable per case yet unjustifiable at very low volume near a high-quality regional center. Conversely, rural or geographically isolated hospitals may justify an in-house program even at lower volume if local treatment reduces travel burden and shortens time to therapy, considerations that carry particular weight for nonprofit and government systems. The authors propose a three-phase implementation timeline: stakeholder engagement, protocol development, and device-specific training; treatment of an initial cohort of straightforward cases with real-time dashboards tracking patient flow; and early outcomes review culminating in an internal playbook that consolidates workflows and supports onboarding and growth.

Ultimately, the authors argue that a high-performing radioembolization practice is best understood as a service line rather than a procedure. Durable, reproducible outcomes require an intentional infrastructure linking multidisciplinary decision-making, evidence-based selection, personalized dosimetry, nuclear medicine partnership, trained procedural teams, coordinated nursing navigation, and longitudinal outcome tracking. When leadership support, patient-centered education, and continuous process improvement are deliberately built in, the therapy can expand access to advanced liver-directed treatment, reduce fragmentation of care, and strengthen the broader hepatobiliary oncology ecosystem. The future of radioembolization, they conclude, depends not only on better devices, dosimetry, and trials, but on building systems capable of delivering the therapy safely, consistently, and in alignment with patient goals.

Subject of Research: Building and sustaining high-performing yttrium-90 radioembolization programs for liver cancer

Article Title: Building a high-performing yttrium-90 radioembolization practice: from evidence to experience

Article References: Malone, C., Friend, C., Schmitt, B., Siskin, G., & Newton, I. (2026). Building a high-performing yttrium-90 radioembolization practice: from evidence to experience. CVIR Oncology, 2(1), Article 30. https://doi.org/10.1007/s44343-026-00064-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00064-0

Keywords: yttrium-90, radioembolization, hepatocellular carcinoma, radiation segmentectomy, personalized dosimetry, liver-directed therapy, interventional radiology, nuclear medicine, transplant bridging, multidisciplinary care, nurse coordinator, program development

The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry

The technique is a hybrid of two established concepts in interventional radiology. Radiation segmentectomy delivers an ablative dose of yttrium-90 glass microspheres directly into the artery feeding the tumor, achieving intense local tumor control. Radiation lobectomy, by contrast, treats the entire tumor-bearing lobe with a moderate dose that induces atrophy of the treated parenchyma, redirecting portal blood flow and growth signals to the untreated lobe, which compensates by enlarging. Modified radiation lobectomy combines these effects in a single procedure: a segmental or two-adjacent-segment boost above 190 Gy for tumor control, layered onto a lobar dose between 80 and 120 Gy to drive hypertrophy of the future liver remnant. In this study, the mean lobar prescribed dose was 198 plus or minus 58 Gy, with a mean segmental boost of 226 plus or minus 153 Gy, and patients received an average of 1.6 segmental doses.

The standard alternative for expanding a future liver remnant is portal vein embolization, which reliably induces hypertrophy but offers no direct tumor treatment, leaving a window during which cancer can progress. Transarterial chemoembolization controls tumors but produces less predictable liver growth and typically requires staged procedures. Modified radiation lobectomy uniquely merges tumor control and remnant augmentation in one session, which is why the researchers at an academic medical center in Colorado turned to it for patients whose tumors were unresectable by imaging criteria or biopsy, who had preserved liver function classified as Child-Pugh A, an Eastern Cooperative Oncology Group performance status of two or less, satisfactory lung shunt fractions, and no extrahepatic disease.

Between January 2019 and April 2022, fifteen consecutive patients underwent the procedure with the intention of bridging to curative resection. The cohort included seven women and eight men with a mean age of 66 years, ranging from 41 to 84. Seven had hepatocellular carcinoma, six of them at intermediate BCLC stage B and one at advanced stage C with portal vein tumor invasion, while eight had intrahepatic cholangiocarcinoma, five of whom had also received neoadjuvant gemcitabine-cisplatin chemotherapy. The mean index tumor size was a formidable 7.8 centimeters, with the largest measuring 16.2 centimeters. All patients had preserved hepatic function, and seven had underlying liver disease, including hepatitis C, alcohol-related injury, and metabolic dysfunction-associated steatotic liver disease.

Treatment planning was individualized through multidisciplinary tumor board discussion and surgical volumetric assessment. Earlier patients underwent planar macroaggregated albumin dosimetry with single-compartment calculations, while later patients benefited from SPECT/CT-based multicompartment personalized dosimetry using dedicated software. In that subgroup, the average perfused tumor absorbed dose reached 576 plus or minus 284 Gy, the average normal tissue dose was 206 plus or minus 95 Gy, the perfused fraction of the liver averaged 63 percent, and the cumulative lung absorbed dose averaged 16.4 Gy. Follow-up with triphasic CT or MRI occurred at one and three months and then at three-month intervals, with volumetric analysis at every time point using the Couinaud methodology and standardized future liver remnant calculations based on body surface area.

The results were remarkable on both fronts. Every one of the fifteen patients showed an objective tumor response by modified RECIST criteria at thirty days, with 40 percent achieving a complete response and 60 percent a partial response; by ninety days, the complete response rate rose to 53 percent as two additional partial responders converted. Meanwhile, the median future liver remnant increased by 12 percent at thirty days and 30 percent at sixty to ninety days. Median standardized future liver remnant climbed from 31 percent at baseline to 36 percent at one month and 40 percent by two to three months. Notably, hypertrophy was similar in cirrhotic and non-cirrhotic patients, and no difference emerged between hepatocellular carcinoma and cholangiocarcinoma, suggesting the volumetric effect is robust across liver conditions and tumor types.

Safety was equally encouraging. There were no major procedure-related complications, no grade three or higher hepatotoxicity by CTCAE version 5.0 criteria, and no cases of cholangitis, cholecystitis, gastric ulcers, pneumonitis, or radiation-induced liver disease. One patient experienced nausea and vomiting lasting ten days, and no patient required extended hospitalization or readmission within thirty days. This favorable profile likely reflects careful selection of patients with preserved baseline liver function and multidisciplinary evaluation, consistent with prior work showing that yttrium-90 treatment of more than 60 percent of the liver can be safe when an adequate functional remnant is maintained.

The surgical conversion rate was the standout finding. Twelve of the fifteen patients, or 80 percent, became technically eligible for curative-intent surgery, a figure substantially higher than the 16 to 20 percent conversion rates reported in earlier modified radiation lobectomy studies. Three patients were excluded by new disease progression in the contralateral liver or lungs, or inadequate remnant growth. Of the twelve eligible patients, one declined surgery and one resection was aborted because cholangiocarcinoma encased the hepatic vein confluence. Ultimately, ten patients underwent major hepatectomy, including four extended right and four standard right hepatectomies and one extended left hepatectomy, or liver transplantation in one case, at a mean of 122 plus or minus 77 days after radioembolization. Every completed resection achieved negative margins, an R0 outcome that is the surgical gold standard.

Pathology revealed a more nuanced picture. Among eight patients with available data, median tumor necrosis was 57.5 percent, ranging from 30 percent to more than 90 percent, and necrosis did not correlate with imaging response or absorbed dose. The authors attribute this variability to large, heterogeneous tumors with uneven microsphere distribution and to the relatively short interval between treatment and explantation. Despite this, overall survival after surgery remained 80 percent. Two patients with cholangiocarcinoma died within days of surgery from infectious complications, while the remaining eight resected patients showed no evidence of recurrence over an average follow-up of 39 months. Median overall survival was 61 months for hepatocellular carcinoma patients but only 19 months for those with cholangiocarcinoma, underscoring that tumor biology, not technical success, remains the dominant determinant of long-term outcome.

The study has clear limitations: it was retrospective, single-center, and small, with heterogeneous dosimetry methods and no comparator group receiving portal vein embolization or chemoembolization. Yet the message is compelling. Modified radiation lobectomy achieved universal tumor response, meaningful remnant hypertrophy, and an 80 percent surgical eligibility rate in patients whose tumors were once deemed unresectable, all with an excellent safety profile. The findings echo larger evidence, including the updated DOSISPHERE-01 analysis and the prospective PROACTIF cohort, showing that patients who reach curative surgery after yttrium-90 therapy enjoy substantially better survival than those managed nonoperatively. Larger prospective trials comparing modified radiation lobectomy with established bridging strategies are still needed, but for carefully selected patients with large primary liver cancers, this single-procedure approach may be transforming the boundary between inoperable and curable.

Subject of Research: Modified yttrium-90 radiation lobectomy as a bridge to curative surgery for primary liver cancer

Article Title: Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes

Article References: Malavia, M., Lindquist, J., Marchak, K., Eliason, G., Trivedi, P., & Casadaban, L. (2026). Modified radiation lobectomy as a bridge to curative surgery: tumor response, future liver remnant hypertrophy, and surgical outcomes. CVIR Oncology, 2(1), Article 29. https://doi.org/10.1007/s44343-026-00059-x

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00059-x

Keywords: modified radiation lobectomy, yttrium-90 radioembolization, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, future liver remnant hypertrophy, liver resection, radiation segmentectomy, portal vein embolization, surgical conversion, tumor response, interventional radiology, liver cancer

Copper is an indispensable trace element, serving as a cofactor for enzymes involved in respiration, antioxidant defense, and connective tissue formation. Yet when copper homeostasis collapses, the consequences for a cell can be fatal in a way that scientists only began to define in 2022. That year, Peter Tsvetkov and colleagues reported in Science that excess mitochondrial copper binds directly to lipoylated components of the tricarboxylic acid cycle, the enzymatic engine at the heart of mitochondrial metabolism. The resulting accumulation of lipoylated TCA cycle proteins triggers a distinctive form of proteotoxic stress that the authors named cuproptosis, setting it apart from apoptosis, necrosis, and other better-known death programs. Crucially, the process depends on the mitochondrial protein ferredoxin 1, or FDX1, which regulates protein lipoylation through its interaction with the lipoic acid synthase LIAS.

What makes this mechanism so intriguing for liver cancer is a biological paradox. Hepatocellular carcinoma cells frequently exhibit elevated copper metabolism, importing and distributing the metal aggressively to fuel their proliferative demands. But the same dependence appears to raise their vulnerability: when copper overload is pharmacologically forced into the mitochondria, these copper-hungry cells die disproportionately. Earlier work from Tsvetkov’s group had shown that highly lipoylated, mitochondria-rich tumors are especially sensitive to elesclomol, an investigational copper ionophore that ferries copper ions into the mitochondrial interior. Disulfiram, an old alcohol-aversion drug that acts as a copper ionophore, has shown similar copper-dependent toxicity against tumor cells in multiple preclinical models, and recent studies have linked DLAT, a lipoylated enzyme of the pyruvate dehydrogenase complex, to elesclomol sensitivity specifically in hepatocellular carcinoma.

The iron side of the equation is equally consequential. Ferroptosis, first described in 2012, is a form of regulated cell death driven by iron-dependent lipid peroxidation. When the antioxidant systems that normally reduce lipid hydroperoxides falter, particularly the glutathione–glutathione peroxidase 4, or GSH–GPX4, axis, polyunsaturated fatty acids in cellular membranes undergo a radical chain reaction that ruptures the lipid bilayer. The liver, as the body’s principal iron storage and metabolic organ, is exquisitely sensitive to this chemistry. Hepatocellular carcinoma cells, meanwhile, must constantly manage iron influx and oxidative stress to survive, and numerous studies have documented that manipulating iron availability, lipid composition, and antioxidant capacity can tip these cells into ferroptotic death.

The review pays particular attention to the regulatory networks that determine how sensitive a given hepatocellular carcinoma cell is to ferroptosis. Nuclear factor erythroid 2–related factor 2, or NRF2, a master transcriptional regulator of antioxidant responses, emerges as a central node. When NRF2 signaling is active, cells upregulate glutathione synthesis, iron efflux, and a battery of cytoprotective enzymes, effectively raising a shield against lipid peroxidation. FSP1, a ferroptosis suppressor protein that reduces coenzyme Q10 at the plasma membrane, provides a parallel rescue pathway that operates independently of glutathione. Both defenses can be subverted: work from Ren and colleagues showed that overcoming the compensatory elevation of NRF2 rendered hepatocellular carcinoma cells markedly more vulnerable to disulfiram/copper-induced ferroptosis, while other studies have demonstrated that blocking the cystine transporter xCT, which feeds glutathione synthesis, cooperates lethally with copper-driven stress.

It is at this intersection that the review’s central thesis emerges. Copper toxicity and ferroptosis are not isolated programs; they converge on shared metabolic vulnerabilities. Mitochondrial copper overload destabilizes iron-sulfur clusters, the ancient cofactors that support respiratory and repair enzymes, and this destabilization can itself sensitize cells to lipid peroxidation through iron regulatory proteins. More strikingly, glutathione sits at the crossroads of both pathways. The antioxidant tripeptide neutralizes copper-driven oxidative stress on one hand and fuels GPX4-mediated suppression of ferroptosis on the other. Experimental studies in primary liver cancer have shown that ferroptosis inducers enhance cuproptosis triggered by copper ionophores, and that disulfiram/copper treatment consumes glutathione in a way that launches what one team described as a cascade of ferroptosis and cuproptosis when xCT compensation is simultaneously blocked.

The therapeutic implications are substantial. Standard first-line drugs for advanced hepatocellular carcinoma, including sorafenib and lenvatinib, already exert part of their activity through ferroptosis-related mechanisms; lenvatinib, for example, has been shown to induce ferroptosis via fibroblast growth factor receptor-4 inhibition, while sorafenib sensitivity is modulated by metallothioneins and antioxidant pathways. Layering copper ionophores on top of these agents could push tumor cells past a metabolic tipping point that single-agent therapy never reaches. Nanotechnology is accelerating this vision: research groups have developed reactive oxygen species–responsive nanoparticles co-delivering elesclomol and copper together with anti–PD-L1 immunotherapy, as well as injectable hydrogel systems that combine cuproptosis induction with stemness inhibition to overcome lenvatinib resistance. A 2026 study in Antioxidants described a ROS-responsive nanoplatform that targets both cuproptosis and ferroptosis for synergistic therapy against hepatocellular carcinoma, illustrating how rapidly the dual-targeting concept is moving from theory toward experimental implementation.

The tumor microenvironment adds a further dimension of complexity, and opportunity. Both cuproptosis and ferroptosis are immunologically loud forms of cell death: dying cells release damage-associated molecular patterns and oxidized lipids that can stimulate antitumor immunity, and vaccination with early ferroptotic cancer cells has been shown to induce efficient antitumor immune responses. Multiomics and single-cell sequencing analyses have linked cuproptosis signatures to the immunosuppressive architecture of tumors, while ferroptotic tumor cells can enhance the efficacy of checkpoint inhibitors. Yet the picture is not uniformly favorable. Some work has found that disulfiram combined with copper stabilizes PD-L1 in hepatocellular carcinoma, potentially inducing immunosuppression, a reminder that metal-based therapies must be calibrated carefully if they are to synergize with, rather than undermine, immunotherapy. Macrophage polarization, exosome-mediated signaling, and the metabolic state of stromal cells all modulate how these death programs play out in vivo.

The review’s authors are candid about the limits of the current evidence. Direct clinical data demonstrating that pharmacological induction of cuproptosis, or coordinated cuproptosis–ferroptosis targeting, benefits patients with hepatocellular carcinoma are still lacking. Copper chelation trials, trientine-based antiangiogenic strategies, and disulfiram repurposing efforts have generated encouraging preclinical signals, but translating them into validated regimens will require careful attention to dosing, copper delivery, and patient selection. Biomarkers are an urgent need: serum copper, zinc, and metallothionein levels have been proposed as potential biomarkers for hepatocellular carcinoma, and gene-expression signatures built around FDX1, DLAT, ATP7A, and other cuproptosis-related genes are being explored for prognostic and predictive value. Determining which tumors are copper-vulnerable, which rely on NRF2 or FSP1 for ferroptosis resistance, and which harbor metabolic contexts that favor one death program over the other will be essential for rational combination therapy.

Even with these caveats, the synthesis marks a conceptual shift in how liver cancer might be treated. Rather than viewing copper and iron merely as nutrients that tumors consume, the field increasingly regards their homeostatic control as a pair of interlocking kill switches. Disrupting mitochondrial copper handling destabilizes the metabolic core of the cell; dismantling antioxidant defenses unleashes iron-catalyzed membrane destruction; and because glutathione and related systems guard against both threats simultaneously, a single well-designed intervention can pull two levers at once. With combination strategies already showing synergy in preclinical liver cancer models, and nanoparticle delivery platforms maturing quickly, the copper–iron crosstalk framework offers hepatocellular carcinoma research one of its most mechanistically grounded and therapeutically tantalizing frontiers in years.

Subject of Research: Cuproptosis and ferroptosis as coordinated therapeutic targets in hepatocellular carcinoma

Article Title: Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma

Article References: Xie, X., Cao, H., Chen, H., Zhang, S., & Han, Z. (2026). Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma. Medical Oncology, 43(10), Article 268. https://doi.org/10.1007/s12032-026-03399-z

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03399-z

Keywords: cuproptosis, ferroptosis, hepatocellular carcinoma, copper metabolism, iron metabolism, GPX4, NRF2, FDX1, disulfiram, elesclomol, glutathione, targeted therapy

The paradox at the heart of the work is one that has fascinated cancer biologists for years: although reactive oxygen species, or ROS, are often painted as molecular vandals that damage DNA and drive tumor formation, cancer cells actually live dangerously close to the edge of oxidative tolerance. Having adapted to a certain baseline of ROS, they depend heavily on antioxidant defenses to keep levels from tipping into lethal territory. Pushing ROS past that threshold has therefore emerged as a promising therapeutic concept, and the Nanchang team set out to test whether p-coumaric acid could serve as the tipping force.

In a battery of in vitro experiments, the researchers exposed hepatocellular carcinoma cells to the compound and measured its effects on growth, proliferation, migration, and survival. The results were unambiguous. p-Coumaric acid significantly inhibited the growth and proliferation of the cancer cells, impeded their ability to migrate in wound healing and Transwell assays, and triggered the characteristic physical hallmarks of programmed cell death, including cell shrinkage. Flow cytometry confirmed that the treated cells were dying by apoptosis, and further analysis showed that the compound suppressed the levels of anti-apoptotic and pro-proliferative proteins that liver cancer cells rely on to survive.

The mechanistic story, however, is where the study becomes technically compelling. Using measurements of mitochondrial function, the team found that p-coumaric acid reduced the mitochondrial membrane potential and cut ATP production in the cancer cells. This energetic collapse is significant because mitochondria are both the power plants of the cell and a major source of ROS: when the electron transport chain is disrupted, electrons leak and combine with oxygen to form superoxide and related reactive species. By destabilizing mitochondrial function, the compound effectively opened the floodgates for endogenous ROS accumulation, drowning the cancer cells in their own reactive byproducts.

The researchers then turned their attention to the cell’s principal antioxidant safety valve, the Nrf2 signaling pathway. Nrf2, or nuclear factor erythroid 2-related factor 2, is a transcription factor that, when activated, switches on a broad program of antioxidant and detoxification genes, including heme oxygenase-1, or HO-1. In many tumors, Nrf2 is constitutively active, granting cancer cells remarkable resistance to oxidative stress and to chemotherapy. The team found that p-coumaric acid inhibits this pathway in liver cancer cells, removing a critical layer of protection and allowing ROS levels to climb even higher. The compound thus attacks from two directions at once: it boosts ROS production through mitochondrial dysfunction while simultaneously dismantling the defenses that would normally neutralize it.

To confirm that the Nrf2 arm of the mechanism was genuinely responsible for part of the effect, the researchers used hemin, an agonist of the antioxidant enzyme HO-1. When hemin was applied, it counteracted the inhibitory effect of p-coumaric acid on the viability of the cancer cells, demonstrating that re-engaging the antioxidant machinery could rescue the tumor cells from the oxidative assault. This pharmacological rescue experiment strengthens the causal chain linking Nrf2 inhibition, ROS accumulation, and cell death, rather than leaving the pathway as a mere correlation observed in treated cells.

The in vivo evidence proved equally persuasive. Using a subcutaneous xenograft mouse model of hepatocellular carcinoma, the team showed that p-coumaric acid suppressed tumor growth in living animals. Crucially, when the mice were also treated with N-acetylcysteine, a well-established ROS scavenger, the anti-cancer effects of the compound were reversed. This is the kind of result that carries real weight in redox biology: if mopping up reactive oxygen species abolishes the therapeutic effect, then ROS accumulation is not a side effect but the engine of the compound’s anti-tumor activity. The N-acetylcysteine experiment therefore serves as the linchpin connecting the cellular mechanism to the whole-animal outcome.

The findings also sit within a growing body of literature on p-coumaric acid, a compound already known for anti-inflammatory, antioxidant, and protective effects in contexts ranging from diabetic kidney disease to lung inflammation. Earlier work had hinted at anti-cancer potential, including studies showing apoptotic effects in colon cancer cells and cytotoxicity in neuroblastoma cells through ROS-mediated mitochondrial dysfunction, as well as nanoparticle delivery strategies for breast cancer therapy. What distinguishes the new study is its systematic dissection of the compound’s action in hepatocellular carcinoma specifically, a cancer for which treatment options remain limited and recurrence rates remain high, and its dual demonstration of mitochondrial and Nrf2-targeted mechanisms backed by in vivo validation.

The broader implications are twofold. First, the work reinforces the emerging view that redox homeostasis is a pivotal regulator of liver cancer progression and that deliberately disrupting it is a viable therapeutic strategy, one shared by other natural products and by synthetic agents designed to induce oxidative stress in tumors. Second, it suggests that p-coumaric acid, a cheap and widely available dietary molecule with a favorable safety profile in other contexts, could be developed further as a lead compound, whether administered directly, formulated into targeted delivery systems, or combined with existing therapies to sensitize tumors. The authors, led by Jiahao Zheng and corresponding author Yange Liu of the School of Basic Medical Sciences at Nanchang University, caution that the findings come from cell culture and mouse models, and that translating them into clinical practice will require pharmacokinetic studies, dosing optimization, and eventually human trials. Still, the study adds a compelling entry to the pharmacopeia of plant-derived molecules under investigation for cancer therapy, and it underscores a lesson that modern oncology keeps relearning: sometimes the most effective way to kill a cancer cell is not to poison it directly, but to strip away its defenses and let the chemistry it cannot escape do the rest.

Subject of Research: The anti-cancer effects and ROS-based mechanism of p-coumaric acid in hepatocellular carcinoma

Article Title: p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation

Article References: Zheng, J., Zhang, Q., Wang, L., Yuan, M., Wang, Y., Wei, X., Lian, H., Liu, X., & Liu, Y. (2026). p-Coumaric acid inhibits hepatocellular carcinoma through promoting ROS accumulation. Medical Oncology, 43(10), Article 279. https://doi.org/10.1007/s12032-026-03367-7

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03367-7

Keywords: p-coumaric acid, hepatocellular carcinoma, reactive oxygen species, Nrf2 pathway, mitochondrial dysfunction, apoptosis, liver cancer, oxidative stress, natural compounds, HO-1, N-acetylcysteine, cancer therapy

The research, conducted by scientists from the China Academy of Chinese Medical Sciences and Fujian University of Traditional Chinese Medicine, addresses a major challenge in liver cancer treatment. Hepatocellular carcinoma often develops in the context of chronic liver disease and can be difficult to control once it has progressed. Although surgery, ablation, immunotherapy, targeted drugs, and chemotherapy can benefit selected patients, treatment resistance and disease recurrence remain widespread. Artesunate is already widely used against malaria, giving it an established pharmacological history and a well-characterized clinical profile. However, the molecular basis of its activity against cancer has remained incompletely understood.

The investigators first examined how artesunate affected the survival and growth of two human hepatocellular carcinoma cell lines, HepG2 and MHCC-97H. Using the CCK8 assay, which measures cellular metabolic activity as an indicator of viability and proliferation, they found that artesunate inhibited both cell lines in a concentration-dependent manner. HepG2 cells were more sensitive than MHCC-97H cells, suggesting that differences in metabolic state or drug-response pathways may influence the treatment’s effectiveness. Additional experiments showed that artesunate reduced cancer-cell proliferation and increased the proportion of cells undergoing apoptosis, a tightly regulated form of cell death that is frequently disabled in tumors.

The study also examined artesunate in an orthotopic mouse model, in which HepG2 cells were injected into the liver to reproduce a more realistic tumor environment than conventional subcutaneous models. Animals receiving low, middle, or high doses of artesunate showed evidence of increased tumor-cell apoptosis. TUNEL staining, which detects fragmented DNA associated with programmed cell death, and Hoechst staining, which reveals changes in nuclear structure, both supported the conclusion that artesunate promoted apoptosis in the tumors. The effects were compared with control animals and with a group receiving 5-fluorouracil, a commonly used anticancer drug. These experiments provided in vivo support for the cellular findings, although additional animal and clinical studies will be necessary to determine whether the effect can be translated into a useful treatment.

The researchers connected artesunate’s activity to sphingolipid metabolism, a biochemical network that produces and regulates lipids involved in membrane structure, cell signaling, inflammation, and cell death. GBA normally helps break down glucosylceramide, a glycosphingolipid, into downstream metabolic products. When GBA was inhibited by artesunate, glucosylceramide-related metabolites accumulated and the balance of cellular sphingolipids was disturbed. Such metabolic changes can place stress on organelles and alter signaling pathways that control survival. In the treated liver cancer cells, this disruption was associated with mitochondrial dysfunction, a critical event because mitochondria regulate the intrinsic pathway of apoptosis.

The study describes a signaling sequence linking altered lipid metabolism to mitochondrial apoptosis: GBA, ceramide, cathepsin D, alpha-synuclein, BID, and BAX. In this proposed GBA–ceramide–CTSD–α-syn–BID–BAX axis, artesunate first suppresses GBA activity, altering ceramide metabolism. The resulting biochemical imbalance interferes with the maturation or function of cathepsin D, a lysosomal protease. It also promotes the accumulation of alpha-synuclein, a protein better known for its association with neurodegenerative disease but increasingly recognized as a regulator of cellular stress and organelle communication. These changes facilitate cleavage of BID and increase the activity or abundance of BAX, two important components of the mitochondrial death pathway. BAX can promote mitochondrial membrane permeabilization, allowing apoptotic factors to escape and activate downstream caspases, the enzymes that dismantle the cell.

Rescue experiments strengthened the proposed mechanism. When researchers supplemented cells with ceramide, they were able to influence the apoptotic response, supporting the idea that sphingolipid imbalance lies between GBA inhibition and mitochondrial damage. Conversely, suppressing alpha-synuclein reduced key effects of artesunate, indicating that alpha-synuclein accumulation is not simply a passive consequence of treatment but contributes to the death signal. The researchers also tested LTI-291, described in the study as a GBA enzyme activator, in combination with high-dose artesunate. The combined treatment helped probe whether restoring GBA-related activity could counteract artesunate’s effects. Together, these interventions provided functional evidence that the pathway is central to the drug’s anticancer action rather than being an incidental molecular signature.

A particularly significant part of the work focused on the physical interaction between artesunate and GBA. Through computational modeling and biochemical analyses, the researchers identified three amino-acid residues—tyrosine 313, glutamate 340, and asparagine 396—as important potential contact points within the enzyme’s active site. Site-directed mutagenesis was then used to replace selected residues and test their importance experimentally. Mutations affecting E340 and N396 substantially weakened artesunate binding and reduced GBA enzymatic activity. The altered enzyme also lost much of its ability to transmit the downstream apoptotic response induced by artesunate. These results support a direct target-engagement model in which the drug’s chemical structure fits into a functional region of GBA and changes the enzyme’s behavior.

The findings are notable because they move beyond the observation that artesunate can kill cancer cells and begin to explain why. Drug repurposing often starts with a promising biological effect, but successful development requires knowledge of the target, the binding site, the responsive cancer subtypes, and the mechanisms that may produce resistance. By defining GBA as a direct molecular target and connecting it to a lipid-regulated apoptotic pathway, the study offers several possible directions for future research. GBA expression or sphingolipid profiles might eventually help identify tumors most likely to respond, while combinations involving ceramide metabolism, lysosomal function, or mitochondrial apoptosis could potentially improve treatment activity.

At the same time, the results should not be interpreted as evidence that artesunate is already an established liver cancer therapy. The experiments were performed mainly in cultured cell lines and mouse models, systems that cannot fully reproduce the genetic diversity, immune environment, drug metabolism, and treatment history of human tumors. The greater sensitivity of HepG2 cells compared with MHCC-97H cells also highlights the possibility that response depends on tumor-specific biology. Future work will need to test the mechanism in patient-derived organoids, genetically diverse xenograft models, and carefully designed pharmacological studies. Long-term safety, optimal dosing, interactions with current liver cancer treatments, and the effects of artesunate on healthy liver tissue will also require detailed evaluation.

Published in Genes & Diseases, the study presents artesunate as more than an antimalarial compound with broad anticancer activity. It identifies a defined enzyme target, maps critical binding residues, and traces a mechanistic route from altered sphingolipid metabolism to mitochondrial apoptosis in hepatocellular carcinoma. If the findings are confirmed in clinically relevant models and human studies, GBA-targeted strategies could expand the therapeutic possibilities for a cancer that continues to demand more effective and durable treatments. For now, the work provides a compelling molecular blueprint for investigating how an established medicine might be redesigned or repurposed to exploit metabolic weaknesses in liver cancer.

Subject of Research: Artesunate-induced apoptosis and GBA-targeted mechanisms in hepatocellular carcinoma

Article Title: Artesunate directly targets glucosylceramidase to suppress hepatocellular carcinoma proliferation and trigger apoptosis

Web References: https://doi.org/10.1016/j.gendis.2026.102045; https://www.sciencedirect.com/journal/genes-and-diseases

References: Genes & Diseases, DOI: 10.1016/j.gendis.2026.102045

Image Credits: Xia Mao, Xiangying Yan, Yawen Chen, Bingbing Cai, Wenjia Chen, Ya Lin, Na Lin, Yanqiong Zhang

Keywords

Artesunate, hepatocellular carcinoma, liver cancer, glucosylceramidase, GBA, sphingolipid metabolism, ceramide, mitochondrial apoptosis, cathepsin D, alpha-synuclein, BID, BAX, drug repurposing

Radiotherapy is a cornerstone treatment for many cancer types, including HCC, relying heavily on the immune system’s activation—particularly that of CD8⁺ T cells, which play a vital role in targeting and killing tumor cells post-irradiation. However, the new study reveals that PVC, a ubiquitous synthetic plastic polymer, can markedly inhibit the differentiation of these critical immune cells during radiotherapy.

The researchers conducted extensive in vitro and in vivo experiments to simulate the tumor microenvironment and assess the impact of PVC on immune cell behavior. Their data showed that PVC exposure leads to a significant reduction in the proportion of CD8⁺ T cells capable of differentiating into their cytotoxic forms, which are essential for mounting an effective anti-tumor response. This inhibition contributes directly to enhanced radioresistance in HCC cells, effectively enabling tumors to survive and grow despite irradiation.

Mechanistically, the study identifies alterations in key signaling pathways responsible for T cell differentiation, including interferon-gamma (IFN-γ) and T-bet transcription factor activities. PVC appears to interfere with these signals, dampening the immune system’s ability to modulate its response to radiation-induced stress in the tumor environment. This immunosuppressive effect represents a novel mechanism by which a common environmental pollutant can impair cancer treatment outcomes.

Notably, the implications extend beyond the laboratory; the findings raise important public health considerations regarding chronic PVC exposure and its potential to undermine the efficacy of cancer therapies. Given the widespread use of PVC in medical supplies, building materials, and consumer products, these insights highlight a hidden challenge in oncology, where the intersection of environmental toxicology and immunotherapy is increasingly relevant.

The study also opens new avenues for therapeutic intervention. If the inhibitory effects of PVC on CD8⁺ T cell differentiation can be counteracted, patients undergoing radiotherapy for HCC might experience improved treatment response rates. Potential strategies could include the development of adjuvant therapies aimed at restoring immune cell functionality or reducing environmental PVC exposure during cancer management.

Overall, this research marks a significant advance in our understanding of the complex interactions between environmental pollutants and cancer treatment. By elucidating the role of PVC in promoting tumor radioresistance through immune suppression, Zhang and colleagues provide a critical foundation for future studies aimed at optimizing radiotherapy efficacy in the face of environmental challenges. As cancer care moves toward increasingly personalized and multifaceted approaches, recognizing and mitigating such external factors could prove vital in improving patient outcomes.

Subject of Research: Polyvinyl chloride’s impact on radiotherapy and immune response in hepatocellular carcinoma

Article Title: Polyvinyl chloride promotes radioresistance in hepatocellular carcinoma by inhibiting radiotherapy-induced CD8⁺ T cell differentiation

Article References:

Zhang, H., Lu, Y., Xiong, H. et al. Polyvinyl chloride promotes radioresistance in hepatocellular carcinoma by inhibiting radiotherapy-induced CD8⁺ T cell differentiation. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75415-9

Image Credits: AI Generated

Clinical trials investigating systemic therapies for uHCC have traditionally excluded patients with CP B cirrhosis, reflecting concerns regarding safety and diminished liver reserve. This study addresses this crucial gap by performing a single-center, retrospective analysis of 94 uHCC patients treated with ICIs plus AAs between 2020 and 2024. Among them, 63 had Child-Pugh A (CP A) cirrhosis, while 31 presented with CP B cirrhosis, allowing for a comparative evaluation of treatment outcomes and tolerability.

The study’s findings reveal an encouraging overall objective response rate (ORR) of 44.7% across the whole cohort, with a disease control rate (DCR) of 72.3%. These clinical endpoints offer a promising perspective on the tumor response to combination therapy in a population with traditionally poor prognoses. Median progression-free survival (mPFS) was reported at 6.3 months, and notably, the median overall survival (mOS) reached 28.3 months, underscoring sustained benefits in systemic therapy for uHCC patients.

When stratified by liver function status, patients with CP A cirrhosis exhibited higher ORR (50.8%) compared to those with CP B cirrhosis (32.3%), though this difference approached but did not reach statistical significance (P = 0.089). Similarly, DCR and mPFS were numerically superior in the CP A group but lacked statistical significance. Intriguingly, mOS demonstrated a marked and statistically significant disparity, favoring the CP A group (39.2 months) over CP B patients (15.9 months, P = 0.035). This dichotomy highlights the profound impact of hepatic functional reserve on long-term survival despite comparable response rates to therapy.

Several prognostic factors independent of cirrhosis status emerged from the analysis. Poor performance status, denoted by an Eastern Cooperative Oncology Group (ECOG) score of 2, prior treatments, and absence of concurrent locoregional therapies were associated with diminished objective responses. Additionally, CP B cirrhosis and advanced Barcelona Clinic Liver Cancer (BCLC) stages C or D independently predicted worse overall survival, underscoring the nuanced interactions between tumor burden, liver function, and systemic therapy efficacy.

The safety profile of ICIs combined with AAs was carefully assessed, revealing that an overwhelming majority (93.6%) of patients experienced at least one treatment-related adverse event (TRAE), with 27.7% encountering grade 3 or higher toxicities. Crucially, the incidence and severity of TRAEs did not differ significantly between CP A and CP B subgroups, suggesting that the addition of ICIs and AAs does not disproportionately increase treatment-related risks even in patients with moderately impaired liver function.

Remarkably, 32.3% of patients with CP B cirrhosis demonstrated improvement in their Child-Pugh score following systemic therapy, indicating a potential for therapeutic intervention to not only control tumor progression but also enhance hepatic functional reserve. This finding challenges conventional therapeutic nihilism associated with CP B patients and advocates for a more inclusive approach in clinical practice.

Understanding the mechanistic underpinnings of ICIs combined with AAs in uHCC is essential. Immune checkpoint inhibitors function by unleashing the immune system’s cytotoxic T cells against tumor cells, a mechanism often suppressed in the tumor microenvironment. Antiangiogenic agents complement this by inhibiting vascular endothelial growth factor (VEGF) pathways, effectively starving the tumor of its blood supply and promoting an immunologically active milieu. Their synergy is thought to enhance antitumor immunity and counteract resistance pathways frequently encountered in hepatocellular carcinoma.

The study’s retrospective design, although inherently limited by potential selection biases and confounding variables, offers valuable real-world insights. Incorporating patients with CP B cirrhosis, typically excluded from randomized trials, enhances the generalizability of findings and contributes toward personalized treatment paradigms. However, larger, prospective studies are essential to validate these observations and elucidate optimal treatment sequencing and combination strategies.

Previous research on systemic therapies in uHCC mainly focused on patients with preserved liver function, limiting evidence for CP B populations. This study significantly advances the field by demonstrating that systemic immunotherapy combined with antiangiogenic treatment can be both efficacious and tolerable in these patients, opening new therapeutic avenues. The observed survival benefit and Child-Pugh score improvements further emphasize the need to reconsider exclusion criteria in future clinical trials.

Translating these findings into clinical practice necessitates careful patient selection and monitoring. While ICIs plus AAs show robust efficacy, attention to adverse events remains paramount, particularly in patients with compromised liver function. The comparable safety profiles between Child-Pugh groups provide reassurance but warrant vigilant management to optimize outcomes.

The integration of locoregional therapies alongside systemic treatments appeared to improve objective response rates, underscoring the potential benefit of multimodal approaches in managing uHCC. Combining transarterial chemoembolization, radiofrequency ablation, or other localized interventions with ICIs and AAs may potentiate antitumor effects and prolong survival, as suggested by the independent predictive value of simultaneous locoregional therapy.

Moreover, patient performance status remained a critical determinant of treatment success, emphasizing the importance of pre-treatment evaluation and supportive care to maintain functional capacity. Incorporating comprehensive assessments and potential interventions to improve performance status might broaden eligibility and enhance clinical benefit.

This study’s implications extend beyond clinical outcomes, prompting a paradigm shift in conceptualizing systemic therapy candidacy for uHCC patients with advanced liver disease. By demonstrating safety and efficacy in CP B patients, it challenges existing treatment algorithms and supports a more nuanced, inclusive therapeutic approach balancing risk and benefit.

In conclusion, the retrospective analysis conducted at Beijing You’an Hospital highlights the promise of combining immune checkpoint inhibitors with antiangiogenic agents in the management of unresectable hepatocellular carcinoma among patients with varied liver function statuses. While significant survival differences remain linked to hepatic reserve, the overall favorable safety profile and some improvements in liver function underscore the potential to expand treatment access and improve outcomes for historically underserved patient groups in oncology.

Further well-structured prospective trials with larger cohorts and longer follow-up are imperative to refine patient stratification, optimize dosing regimens, and elucidate combinatory strategies involving ICIs, AAs, and locoregional therapies. Such investigations will be foundational to establishing new standards of care in hepatocellular carcinoma treatment, ultimately aiming to enhance survival and quality of life for patients within this challenging clinical context.

Subject of Research: Evaluation of the efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in unresectable hepatocellular carcinoma patients with Child-Pugh A versus B cirrhosis.

Article Title: Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study.

Article References:
Liu, D., Yang, Z., Wang, L. et al. Comparative efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents for unresectable hepatocellular carcinoma in patients with Child-Pugh A versus B cirrhosis: a single-center, retrospective study. BMC Cancer 25, 1651 (2025). https://doi.org/10.1186/s12885-025-15126-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15126-4

This ground-breaking research centers on the metabolic enzyme ATP citrate lyase (ACLY), a key catalyst in the biochemical conversion of glucose to lipid molecules within liver cells. Tumor cells notoriously hijack this metabolic pathway, exploiting fat synthesis to fuel their unchecked growth and survival. The team at McMaster engineered a pharmacological agent — EVT0185 — designed to selectively inhibit ACLY activity within hepatic tissues. This targeted approach interrupts the tumor’s metabolic lifeline, substantially stunting its progression while sparing other organs from systemic side effects.

Strikingly, the treatment did more than halt tumor growth; it revitalized the immune environment within the liver. Conventional cancer immunotherapy paradigms emphasize the pivotal role of cytotoxic T lymphocytes (CTLs) in recognizing and eradicating cancer cells. However, the McMaster study revealed a surprising actor in the anti-tumoral immune orchestra: B cells. These antibody-producing lymphocytes, long overshadowed by T cells in cancer research, emerged as critical mediators of tumor clearance following ACLY inhibition.

The enhanced immunogenicity of liver tumors post-treatment was unexpected and profound. B cells infiltrated the tumor microenvironment in greater numbers, orchestrating complex immune responses that synergized with other immune components. This novel insight challenges the prevailing dogma that T cells are the sole immune warriors in solid tumors and suggests that modulating cancer metabolism can selectively amplify anti-tumor B cell activity.

At a mechanistic level, ACLY inhibition curtails the intracellular synthesis of acetyl-CoA derived from citrate, disrupting lipid biogenesis critical for membrane formation and energy storage in tumor cells. This lipid deprivation likely induces metabolic stress, exposing tumor-associated antigens and rendering cancer cells more visible to immune surveillance. Additionally, altering tumor metabolism may reshape cytokine profiles in the microenvironment, thereby recruiting and activating B cells more effectively.

Fatty liver disease, medically termed metabolic dysfunction–associated steatotic liver disease (MASLD), affects nearly eight million individuals in Canada alone, with a significant subset progressing to a more severe inflammatory state known as metabolic dysfunction-associated steatohepatitis (MASH). These patients bear a disproportionately high risk of developing aggressive liver cancers such as HCC, which historically has seen dismal survival rates—less than 20% of patients survive beyond five years. The introduction of EVT0185 and its ACLY-targeted mechanism offers a promising avenue to alter this grim prognosis.

In preclinical trials, murine models simulating human MASH coupled with HCC were treated with EVT0185, resulting in a marked reduction in both tumor burden and growth rate. Importantly, treated tumors exhibited heightened susceptibility to immune-mediated destruction, primarily through B cell engagement rather than the anticipated cytotoxic T cell pathways. This discovery opens new investigative directions into B cell biology within cancer and may inspire innovative immunotherapies designed to harness these cells’ full potential.

While promising, the research team acknowledges the complexity inherent in translating these findings to clinical practice. Future studies must unravel the precise immunological cascades initiated by ACLY inhibition, determine the safety and efficacy of EVT0185 in human subjects, and explore whether similar strategies can be effective across diverse malignancies with metabolic dependencies. Moreover, understanding how B cells communicate with other immune subsets in the tumor microenvironment will be crucial in designing comprehensive treatment protocols.

This investigation exemplifies the power of targeting cancer metabolism not merely as a metabolic reprogramming stance but as a strategic lever to remodel immune responses. By switching off a vital metabolic enzyme, researchers have demonstrated a capacity to “unmask” tumors and enlist underappreciated immune players in the eradication effort, thereby expanding the therapeutic landscape beyond conventional cytotoxic and checkpoint inhibitor approaches.

The study was made possible through funding from the Canadian Institutes of Health Research Foundation Grant and collaborative investment from Espervita Therapeutics, underscoring the increasing importance of academia-industry partnerships in advancing translational medicine. Notably, several authors maintain shareholder positions within Espervita, highlighting a close integration of research innovation and biotechnological development.

As this research paves the way for next-generation liver cancer therapies, it also sparks a broader imperative to revisit the metabolic underpinnings across other cancers. Metabolic enzymes like ACLY may constitute a new class of druggable targets capable of simultaneously disabling tumor nutrition and invigorating immune defenses. Such dual-action therapeutics could revolutionize oncological treatment paradigms, addressing resistance mechanisms and poor immunogenicity that have long hampered success.

In summary, the McMaster University and Espervita Therapeutics collaboration reveals a transformative approach to liver cancer treatment by inhibiting ACLY, the pivotal enzyme linking carbohydrate metabolism to fat synthesis. This intervention disrupts tumor metabolic homeostasis, triggers an unexpected B cell-driven immune response, and reduces tumor viability in preclinical models. While human trials are the next critical step, these findings significantly deepen our understanding of cancer immunometabolism and open promising avenues for combating one of the world’s deadliest cancers.

Subject of Research: Liver cancer metabolism and immune system interaction focusing on ACLY enzyme inhibition and B cell-mediated tumor immunity
Article Title: Inhibiting ACLY enhances tumour immunogenicity and resolves MASH-HCC
News Publication Date: 30-Jul-2025
Web References: 10.1038/s41586-025-09297-0
Keywords: Cancer, Liver cancer, Metabolism, Immunotherapy, B cells, ATP citrate lyase, Fatty liver disease, MASLD, MASH, Tumor microenvironment, Hepatocellular carcinoma, Immune metabolism